98%
921
2 minutes
20
Introduction: Homelessness in the United States increased every year since 2016, with a 38% increase from 2023 to 2024. Much of the increase is attributable to rising home and rent costs, economic hardship caused by the recent pandemic, and the ending of protective legislation. Notably, people who experience homelessness have an increased risk of substance use disorders, HIV infection and poorer HIV outcomes than people who are stably housed. The iHouse model aims to develop feasible, effective, and cost-effective tailored approaches to improve health outcomes in this population including life expectancy, overdose, and HIV.
Methods And Analysis: The study will employ Group Model Building methods and use insights from that process to develop an agent-based model simulating the dynamic processes contributing to HIV incidence and treatment, overdose, and life expectancy among people along the housing and homelessness continuum in Denver, CO and San Francisco, CA. The model will evaluate multiple outcomes from 4 conceptual dimensions: (1) movement along the housing continuum, (2) population health (overdose and HIV incidence and life expectancy), (3) budgetary impact, (4) economic value.
Ethics And Dissemination: This study has been approved by the Colorado Institutional Review Board at the University of Colorado under protocol 24-0878. The data generated by this protocol, the methodologies used, and the findings will be made available in a timely manner to other researchers. iHOUSE code and parameter values will be published in Git Hub, such that all model analyses can be reproduced by independent investigators. Documentation of all parameter estimates and model results will be published for independent review and confirmation. In addition, supplemental materials and appendices for the model will be shared on a publicly available website.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355926 | PMC |
http://dx.doi.org/10.3389/fpubh.2025.1623385 | DOI Listing |
Apoptosis
September 2025
Department of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuang, China.
Cardiovascular diseases (CVDs) are a leading cause of death globally, responsible for 32% of all fatalities. They significantly reduce quality of life and life expectancy, while imposing a substantial economic burden on healthcare systems in different countries. High mobility group box 1 (HMGB1), a location-dependent multifunctional protein, plays a significant role in various cell death pathways associated with CVDs.
View Article and Find Full Text PDFBundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
September 2025
School of Health & Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Clarice Pears Building, 90 Byres Road, G12 8TB, Glasgow, UK.
The rate of improvement in life expectancy and mortality slowed considerably in a number of high-income countries from the early 2010s, predating the COVID-19 pandemic by almost a decade. Evidence for different countries, including the separate nations of the United Kingdom (e.g.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, China.
Human papillomavirus (HPV) causes multiple diseases in both sexes. This study evaluates the cost-effectiveness and epidemiological impact - defined as reductions in HPV-related disease cases - of a gender-neutral vaccination (GNV) strategy in China's economically developed metropolises: Beijing, Shanghai, and Guangzhou. A discrete-time Markov model simulated no vaccination, female-only vaccination (FOV), and GNV strategies among 12-year-olds.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFAdv Mater
September 2025
School of Medical Sciences, University of Sydney, Sydney, NSW, 2006, Australia.
The disparity between the global increase in life expectancy and the steady decline in health outcomes with age has been a major driver for developing new ways to research aging. Although this current tools for studying aging outside of the human body-such as animal models and cells in a dish-have improved this fundamental understanding of the markers and key mechanisms underlying this process, several limitations remain. Animal models are poor biological representations of humans and have a weak track record of translating pre-clinical results into successful clinical applications.
View Article and Find Full Text PDF